Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdrostat, works ... and the medical community seems to agree.
At the European Society of Cardiology (ESC) Congress this past weekend, the phase III BaxHTN trial data were unveiled in full.
The response was unusually enthusiastic. According to JPMorgan, a round of applause greeted the results: placebo-adjusted reductions in systolic blood pressure of 8.7mmHg and 9.8mmHg at 12 weeks, significant enough for the lead discussant to label the effect “clinically meaningful”.
More importantly, the efficacy was sustained through Week 32 at the 2mg dose.
This is a promising showing for a drug targeting resistant and uncontrolled hypertension, a field long in need of better options.
UBS described the data as “competitive” and noted that efficacy and safety were broadly in line with lorundrostat, a rival treatment developed by Mineralys.
The commercial path, however, is unlikely to be straightforward.
UBS pointed out that generic spironolactone, a cheap, entrenched treatment, may remain the first step for many patients under insurer guidance.
That could limit initial uptake, though AstraZeneca has already priced in conservative assumptions. UBS assigns just a 60% probability to $3 billion in peak sales for hypertension alone, contributing around 1.1% to net present value.
Even so, baxdrostat is one of the more material pipeline assets in AstraZeneca’s vast portfolio, and one of the few late-stage programmes that could plausibly hit multi-billion dollar peak sales.
Investors may not be fully attuned to its potential, in part because of macro headwinds facing the sector and the looming Phase III readout for Dato-DXd in lung cancer, expected next year.
There’s also a distant competitive threat to keep an eye on. Roche and Alnylam are pushing ahead with zilebesiran, an investigational treatment dosed just twice a year.
The drug failed to meet its primary endpoint in the recent KARDIA-3 trial, but a subgroup showed signs of efficacy.
A cardiovascular outcomes study is now being prepared, though UBS attaches a lower 40% probability to peak sales of $2.5 billion.
For now, baxdrostat looks to have a head start: both in terms of data and market readiness.